Insulin

Fast track status received for VLD-Glucagon

Published in Medical Letter on the CDC and FDA, October 30th, 2005

DiObex, Inc., a biotechnology company developing therapeutics for the treatment of metabolic diseases, announced that the U.S. Food & Drug Administration (FDA) has granted fast track status to one of the company's lead drug candidates, Very Low Dose Glucagon (VLD-Glucagon), to prevent hypoglycemia (low blood sugar) associated with insulin intensification in type 1 diabetes.

Glucagon, a naturally occurring hormone, plays a major role in the body's defenses against hypoglycemia, which is a frequent side effect of insulin use. There are currently no approved therapies to prevent hypoglycemia in type 1 diabetic patients who suffer increasing risk of the condition due to the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-10-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry